Trial
NCT01824303
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Allergan
Collaborators
TARIS Biomedical, Inc.
Condition
Interstitial Cystitis
Intervention
LiRIS 400 mg
Why stopped
This study was terminated early due to company decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-01-26